{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T16:12:46Z","timestamp":1775923966370,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1007\/s11936-005-0034-y","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T09:42:09Z","timestamp":1180863729000},"page":"483-490","source":"Crossref","is-referenced-by-count":5,"title":["Pulmonary embolism: Current treatment options"],"prefix":"10.1007","volume":"7","author":[{"given":"Marc","family":"Meysman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Haentjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"34_CR1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1055\/s-0037-1613230","volume":"88","author":"S Murin","year":"2002","unstructured":"Murin S, Romano PS, White RH: Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002, 88:407\u2013414.","journal-title":"Thromb Haemost"},{"key":"34_CR2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1378\/chest.118.5.1405","volume":"118","author":"M Margaglione","year":"2000","unstructured":"Margaglione M, Brancaccio V, De Lucia D, et al.: Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 2000, 118:1405\u20131411.","journal-title":"Chest"},{"key":"34_CR3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/0003-4819-140-3-200402030-00008","volume":"140","author":"DJ Quinlan","year":"2004","unstructured":"Quinlan DJ, McQuillan A, Eikelboom JW: Low-molecularweight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004, 140:175\u2013183. A good review of the advantages of LMWH over UFH.","journal-title":"Ann Intern Med"},{"issue":"3 suppl","key":"34_CR4","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","volume":"126","author":"HR Buller","year":"2004","unstructured":"Buller HR, Agnelli G, Hull RD, et al.: Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 suppl):401S-428S. An absolute must for all those involved in the treatment of PE. This paper presents a comprehensive review of the clinical data and all courses of action available for the treatment of patients diagnosed with PE.","journal-title":"Chest"},{"key":"34_CR5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","volume":"337","author":"JI Weitz","year":"1997","unstructured":"Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997, 337:688\u2013698.","journal-title":"N Engl J Med"},{"key":"34_CR6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1538-7933.2004.00648.x","volume":"2","author":"H Bounameaux","year":"2004","unstructured":"Bounameaux H, de Moerloose P: Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004, 2:551\u2013554.","journal-title":"J Thromb Haemost"},{"key":"34_CR7","first-page":"799","volume":"122","author":"M Laposata","year":"1998","unstructured":"Laposata M, Green D, Van Cott EM, et al.: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecularweight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998, 122:799\u2013807.","journal-title":"Arch Pathol Lab Med"},{"key":"34_CR8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0037-1614119","volume":"84","author":"V Siguret","year":"2000","unstructured":"Siguret V, Pautas E, Fevrier M, et al.: Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000, 84:800\u2013804.","journal-title":"Thromb Haemost"},{"key":"34_CR9","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0037-1615034","volume":"79","author":"P Mismetti","year":"1998","unstructured":"Mismetti P, Laporte-Simitsidis S, Navarro C, et al.: Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998, 79:1162\u20131165.","journal-title":"Thromb Haemost"},{"key":"34_CR10","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1001\/archinte.162.22.2605","volume":"162","author":"J Nagge","year":"2002","unstructured":"Nagge J, Crowther M, Hirsh J: Is impaired renal function a contraindication to the use of low-molecularweight heparin? Arch Intern Med 2002, 162:2605\u20132609.","journal-title":"Arch Intern Med"},{"key":"34_CR11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1538-7933.2004.00647.x","volume":"2","author":"J Harenberg","year":"2004","unstructured":"Harenberg J: Is laboratory monitoring of low-molecularweight heparin therapy necessary? Yes. J Thromb Haemost 2004, 2:547\u2013550.","journal-title":"J Thromb Haemost"},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1538-7836.2003.00014.x","volume":"1","author":"P Prandoni","year":"2003","unstructured":"Prandoni P: Low molecular weight heparins: are they interchangeable? Yes. J Thromb Haemost 2003, 1:10\u201311.","journal-title":"J Thromb Haemost"},{"key":"34_CR13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1345\/aph.10264","volume":"36","author":"GM McCart","year":"2002","unstructured":"McCart GM, Kayser SR: Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother 2002, 36:1042\u20131057.","journal-title":"Ann Pharmacother"},{"key":"34_CR14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2174\/1381612043452811","volume":"10","author":"J Fareed","year":"2004","unstructured":"Fareed J, Hoppensteadt D, Schultz C, et al.: Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des 2004, 10:983\u2013999.","journal-title":"Curr Pharm Des"},{"key":"34_CR15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/archinte.165.7.733","volume":"165","author":"PS Wells","year":"2005","unstructured":"Wells PS, Anderson DR, Rodger MA, et al.: A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005, 165:733\u2013738.","journal-title":"Arch Intern Med"},{"key":"34_CR16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199709043371002","volume":"337","author":"G Simonneau","year":"1997","unstructured":"Simonneau G, Sors H, Charbonnier B, et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l\u2019Embolie Pulmonaire. N Engl J Med 1997, 337:663\u2013669.","journal-title":"N Engl J Med"},{"key":"34_CR17","doi-asserted-by":"crossref","unstructured":"Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators [no authors listed]. N Engl J Med 1997, 337:657\u2013662.","DOI":"10.1056\/NEJM199709043371001"},{"key":"34_CR18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-134-3-200102060-00009","volume":"134","author":"G Merli","year":"2001","unstructured":"Merli G, Spiro TE, Olsson CG, et al.: Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001, 134:191\u2013202.","journal-title":"Ann Intern Med"},{"key":"34_CR19","first-page":"782","volume":"122","author":"JD Olson","year":"1998","unstructured":"Olson JD, Arkin CF, Brandt JT, et al.: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998, 122:782\u2013798.","journal-title":"Arch Pathol Lab Med"},{"key":"34_CR20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","volume":"119","author":"RA Raschke","year":"1993","unstructured":"Raschke RA, Reilly BM, Guidry JR, et al.: The weight-based heparin dosing nomogram compared with a \u201cstandard care\u201d nomogram. A randomized controlled trial. Ann Intern Med 1993, 119:874\u2013881.","journal-title":"Ann Intern Med"},{"key":"34_CR21","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMe038112","volume":"349","author":"HR Buller","year":"2003","unstructured":"Buller HR, Davidson BL, Decousus H, et al.: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695\u20131702.","journal-title":"N Engl J Med"},{"key":"34_CR22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00001721-200301000-00011","volume":"14","author":"M Reiter","year":"2003","unstructured":"Reiter M, Bucek RA, Koca N, et al.: Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagul Fibrinolysis 2003, 14:61\u201365.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"34_CR23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0049-3848(02)00259-1","volume":"107","author":"K Wahlander","year":"2002","unstructured":"Wahlander K, Lapidus L, Olsson CG, et al.: Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002, 107:93\u201399. A good review of the correct position of thrombolysis in the treatment of PE.","journal-title":"Thromb Res"},{"key":"34_CR24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jama.293.6.736","volume":"293","author":"V Gurewich","year":"2005","unstructured":"Gurewich V: Ximelagatran\u2014promises and concerns. JAMA 2005, 293:736\u2013739.","journal-title":"JAMA"},{"key":"34_CR25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.0000137826.09715.9C","volume":"110","author":"S Wan","year":"2004","unstructured":"Wan S, Quinlan DJ, Agnelli G, et al.: Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004, 110:744\u2013749.","journal-title":"Circulation"},{"key":"34_CR26","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1161\/01.CIR.0000064898.51892.09","volume":"107","author":"N Kucher","year":"2003","unstructured":"Kucher N, Printzen G, Doernhoefer T, et al.: Low probrain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003, 107:1576\u20131578.","journal-title":"Circulation"},{"key":"34_CR27","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/01.CIR.0000074039.45523.BE","volume":"107","author":"N Kucher","year":"2003","unstructured":"Kucher N, Printzen G, Goldhaber SZ: Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003, 107:2545\u20132547.","journal-title":"Circulation"},{"key":"34_CR28","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1378\/chest.122.6.2264","volume":"122","author":"P Pruszczyk","year":"2002","unstructured":"Pruszczyk P, Szulc M, Torbicki A: Cardiac troponins in acute pulmonary embolism. Chest 2002, 122:2264\u20132265.","journal-title":"Chest"},{"key":"34_CR29","first-page":"686","volume":"86","author":"F Trendelenburg","year":"1908","unstructured":"Trendelenburg F: Ueber die operative Behandlung der Embolie der Lungenarterie. Arch Klin Chir 1908, 86:686\u2013700.","journal-title":"Arch Klin Chir"},{"key":"34_CR30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1051-0443(07)61821-1","volume":"12","author":"R Uflacker","year":"2001","unstructured":"Uflacker R: Interventional therapy for pulmonary embolism. J Vasc Interv Radiol 2001, 12:147\u2013164.","journal-title":"J Vasc Interv Radiol"},{"key":"34_CR31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199802123380701","volume":"338","author":"H Decousus","year":"1998","unstructured":"Decousus H, Leizorovicz A, Parent F, et al.: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d\u2019Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998, 338:409\u2013415.","journal-title":"N Engl J Med"},{"key":"34_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1051-0443(07)61287-1","volume":"11","author":"H Lorch","year":"2000","unstructured":"Lorch H, Welger D, Wagner V, et al.: Current practice of temporary vena cava filter insertion: a multicenter registry. J Vasc Interv Radiol 2000, 11:83\u201388.","journal-title":"J Vasc Interv Radiol"},{"key":"34_CR33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1051-0443(07)61590-5","volume":"12","author":"SF Millward","year":"2001","unstructured":"Millward SF, Oliva VL, Bell SD, et al.: Gunther Tulip Retrievable Vena Cava Filter: results from the Registry of the Canadian Interventional Radiology Association. J Vasc Interv Radiol 2001, 12:1053\u20131058.","journal-title":"J Vasc Interv Radiol"},{"key":"34_CR34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/thorax.58.6.470","volume":"58","author":"British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group","year":"2003","unstructured":"British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group: British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003, 58:470\u2013483. The updated British point of view regarding the diagnostic protocol and the treatment of patients with PE.","journal-title":"Thorax"},{"key":"34_CR35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-126-2-199701150-00006","volume":"126","author":"L Harrison","year":"1997","unstructured":"Harrison L, Johnston M, Massicotte MP, et al.: Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997, 126:133\u2013136.","journal-title":"Ann Intern Med"},{"key":"34_CR36","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","volume":"348","author":"PM Ridker","year":"2003","unstructured":"Ridker PM, Goldhaber SZ, Danielson E, et al.: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348:1425\u20131434.","journal-title":"N Engl J Med"},{"key":"34_CR37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","volume":"349","author":"C Kearon","year":"2003","unstructured":"Kearon C, Ginsberg JS, Kovacs MJ, et al.: Comparison of low-intensity warfarin therapy with conventionalintensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003, 349:631\u2013639.","journal-title":"N Engl J Med"},{"key":"34_CR38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1055\/s-0037-1615928","volume":"82","author":"MH Prins","year":"1999","unstructured":"Prins MH, Hutten BA, Koopman MM, et al.: Long-term treatment of venous thromboembolic disease. Thromb Haemost 1999, 82:892\u2013898.","journal-title":"Thromb Haemost"},{"key":"34_CR39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinte.163.11.1285","volume":"163","author":"CJ Dongen van","year":"2003","unstructured":"van Dongen CJ, Vink R, Hutten BA, et al.: The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med 2003, 163:1285\u20131293.","journal-title":"Arch Intern Med"},{"key":"34_CR40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","volume":"345","author":"G Agnelli","year":"2001","unstructured":"Agnelli G, Prandoni P, Santamaria MG, et al.: Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001, 345:165\u2013169.","journal-title":"N Engl J Med"},{"key":"34_CR41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMe038112","volume":"349","author":"HR Buller","year":"2003","unstructured":"Buller HR, Prins MH: Secondary prophylaxis with warfarin for venous thromboembolism. N Engl J Med 2003, 349:702\u2013704.","journal-title":"N Engl J Med"},{"key":"34_CR42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, et al.: Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146\u2013153.","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0034-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-005-0034-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0034-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:52:32Z","timestamp":1559436752000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-005-0034-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s11936-005-0034-y","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}